{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:04:49Z","timestamp":1793333089561,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001036","name":"Claneil Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5U01CA152990"],"award-info":[{"award-number":["5U01CA152990"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helene Ross Bogutz Fund for Ovarian Cancer Early Detection"},{"name":"Mike and Patti Hennessy Foundation"},{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"publisher","award":["891470"],"award-info":[{"award-number":["891470"]}],"id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006800","name":"Honorable Tina Brozman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006800","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shooting for a Cure"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002300","name":"Rivkin Center for Ovarian Cancer","doi-asserted-by":"publisher","award":["Skacel Family Scientific Scholar Award"],"award-info":[{"award-number":["Skacel Family Scientific Scholar Award"]}],"id":[{"id":"10.13039\/100002300","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marjorie S. Stanek and Lowell H. Dubrow Ovarian Cancer Research Center Endowed Fund"},{"name":"Maggie\u2019s Memorial Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long interspersed element 1 (LINE-1) open reading frame 1 protein (ORF1p) expression is a common feature of many cancer types, including high-grade serous ovarian carcinoma (HGSOC). Here, we report that ORF1p is not only expressed but also released by ovarian cancer and primary tumor cells. Immuno-multiple reaction monitoring-mass spectrometry assays showed that released ORF1p is confidently detectable in conditioned media, ascites, and patients\u2019 plasma, implicating ORF1p as a potential biomarker. Interestingly, ORF1p expression is detectable in fallopian tube (FT) epithelial precursors of HGSOC but not in benign FT, suggesting that ORF1p expression in an early event in HGSOC development. Finally, treatment of FT cells with DNA methyltransferase inhibitors led to robust expression and release of ORF1p, validating the regulatory role of DNA methylation in LINE-1 repression in non-tumorigenic tissue.<\/jats:p>","DOI":"10.1038\/s41598-023-28840-5","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T12:05:48Z","timestamp":1674821148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Sho","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gillette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela R.","family":"de Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mendez-Dorantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Ippoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hobday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Doberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan M.","family":"Gysler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Skates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen H.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Drapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"28840_CR1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2020.07.008","volume":"159","author":"L Zheng","year":"2020","unstructured":"Zheng, L. et al. Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990\u20132017. Gynecol. Oncol. 159, 239\u2013247 (2020).","journal-title":"Gynecol. Oncol."},{"key":"28840_CR2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"28840_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"28840_CR4","unstructured":"Kurman, R. J., Carcangiu, M. L., Young, R. H. & Simon Herrington, C. WHO Classification of Tumours of Female Reproductive Organs. (International Agency for Research on Cancer, 2014)."},{"key":"28840_CR5","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1158\/1055-9965.EPI-20-1057","volume":"29","author":"RC Bast Jr","year":"2020","unstructured":"Bast, R. C. Jr. et al. Biomarkers and strategies for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 29, 2504\u20132512 (2020).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"28840_CR6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","volume":"29","author":"PT Kroeger Jr","year":"2017","unstructured":"Kroeger, P. T. Jr. & Drapkin, R. Pathogenesis and heterogeneity of ovarian cancer. Curr. Opin. Obstet. Gynecol. 29, 26\u201334 (2017).","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"28840_CR7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1006\/gyno.2000.5816","volume":"77","author":"JR van Nagell Jr","year":"2000","unstructured":"van Nagell, J. R. Jr. et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol. 77, 350\u2013356 (2000).","journal-title":"Gynecol. Oncol."},{"key":"28840_CR8","first-page":"25","volume":"6","author":"JRJT van NagellHoff Jr","year":"2013","unstructured":"van NagellHoff, J. R. J. T. Jr. Transvaginal ultrasonography in ovarian cancer screening: Current perspectives. Int. J. Womens Health 6, 25\u201333 (2013).","journal-title":"Int. J. Womens Health"},{"key":"28840_CR9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2018.03.050","volume":"149","author":"C Han","year":"2018","unstructured":"Han, C. et al. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecol. Oncol. 149, 585\u2013591 (2018).","journal-title":"Gynecol. Oncol."},{"key":"28840_CR10","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin, R. et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65, 2162\u20132169 (2005).","journal-title":"Cancer Res."},{"key":"28840_CR11","first-page":"3695","volume":"63","author":"I Hellstr\u00f6m","year":"2003","unstructured":"Hellstr\u00f6m, I. et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63, 3695\u20133700 (2003).","journal-title":"Cancer Res."},{"issue":"351","key":"28840_CR12","first-page":"e1","volume":"206","author":"RG Moore","year":"2012","unstructured":"Moore, R. G. et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am. J. Obstet. Gynecol. 206(351), e1-8 (2012).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"28840_CR13","first-page":"6281","volume":"60","author":"CD Hough","year":"2000","unstructured":"Hough, C. D. et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60, 6281\u20136287 (2000).","journal-title":"Cancer Res."},{"key":"28840_CR14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/bmm.09.21","volume":"3","author":"D Sasaroli","year":"2009","unstructured":"Sasaroli, D., Coukos, G. & Scholler, N. Beyond CA125: The coming of age of ovarian cancer biomarkers: Are we there yet? Biomark. Med. 3, 275\u2013288 (2009).","journal-title":"Biomark. Med."},{"key":"28840_CR15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs, I. J. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 387, 945\u2013956 (2016).","journal-title":"Lancet"},{"key":"28840_CR16","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon, U. et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 397, 2182\u20132193 (2021).","journal-title":"Lancet"},{"key":"28840_CR17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamainternmed.2018.0591","volume":"178","author":"SA Narod","year":"2018","unstructured":"Narod, S. A. Is there a future for ovarian cancer screening? JAMA Intern. Med. 178, 611\u2013612 (2018).","journal-title":"JAMA Intern. Med."},{"key":"28840_CR18","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.3390\/ijms19124018","volume":"19","author":"B Ura","year":"2018","unstructured":"Ura, B. et al. Interstitial fluid in gynecologic tumors and its possible application in the clinical practice. Int. J. Mol. Sci. 19, 4018 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"28840_CR19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc.2017.35","volume":"17","author":"KH Burns","year":"2017","unstructured":"Burns, K. H. Transposable elements in cancer. Nat. Rev. Cancer 17, 415\u2013424 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"28840_CR20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrg2640","volume":"10","author":"R Cordaux","year":"2009","unstructured":"Cordaux, R. & Batzer, M. A. The impact of retrotransposons on human genome evolution. Nat. Rev. Genet. 10, 691\u2013703 (2009).","journal-title":"Nat. Rev. Genet."},{"key":"28840_CR21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev.genet.35.102401.091032","volume":"35","author":"EM Ostertag","year":"2001","unstructured":"Ostertag, E. M. & Kazazian, H. H. Jr. Biology of mammalian L1 retrotransposons. Annu. Rev. Genet. 35, 501\u2013538 (2001).","journal-title":"Annu. Rev. Genet."},{"key":"28840_CR22","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","volume":"409","author":"ES Lander","year":"2001","unstructured":"Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860\u2013921 (2001).","journal-title":"Nature"},{"key":"28840_CR23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.gde.2012.02.006","volume":"22","author":"DC Hancks","year":"2012","unstructured":"Hancks, D. C. & Kazazian, H. H. Jr. Active human retrotransposons: Variation and disease. Curr. Opin. Genet. Dev. 22, 191\u2013203 (2012).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"28840_CR24","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1093\/nar\/gkq132","volume":"38","author":"VP Belancio","year":"2010","unstructured":"Belancio, V. P., Roy-Engel, A. M., Pochampally, R. R. & Deininger, P. Somatic expression of LINE-1 elements in human tissues. Nucleic Acids Res. 38, 3909\u20133922 (2010).","journal-title":"Nucleic Acids Res."},{"key":"28840_CR25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1525-1438.2007.01117.x","volume":"18","author":"J Pattamadilok","year":"2008","unstructured":"Pattamadilok, J. et al. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int. J. Gynecol. Cancer 18, 711\u2013717 (2008).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"28840_CR26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2013.12.024","volume":"132","author":"SN Akers","year":"2014","unstructured":"Akers, S. N. et al. LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. Gynecol. Oncol. 132, 462\u2013467 (2014).","journal-title":"Gynecol. Oncol."},{"key":"28840_CR27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ygyno.2017.09.032","volume":"147","author":"Z Xia","year":"2017","unstructured":"Xia, Z. et al. LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers. Gynecol. Oncol. 147, 642\u2013647 (2017).","journal-title":"Gynecol. Oncol."},{"key":"28840_CR28","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1373\/clinchem.2016.257444","volume":"63","author":"D Ardeljan","year":"2017","unstructured":"Ardeljan, D., Taylor, M. S., Ting, D. T. & Burns, K. H. The human long interspersed element-1 retrotransposon: An emerging biomarker of neoplasia. Clin. Chem. 63, 816\u2013822 (2017).","journal-title":"Clin. Chem."},{"key":"28840_CR29","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.ajpath.2014.01.007","volume":"184","author":"N Rodi\u0107","year":"2014","unstructured":"Rodi\u0107, N. et al. Long interspersed element-1 protein expression is a hallmark of many human cancers. Am. J. Pathol. 184, 1280\u20131286 (2014).","journal-title":"Am. J. Pathol."},{"key":"28840_CR30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ajpath.2018.11.005","volume":"189","author":"TR Pisanic 2nd","year":"2019","unstructured":"Pisanic, T. R. 2nd. et al. Long interspersed nuclear element 1 retrotransposons become deregulated during the development of ovarian cancer precursor lesions. Am. J. Pathol. 189, 513\u2013520 (2019).","journal-title":"Am. J. Pathol."},{"key":"28840_CR31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.humpath.2019.06.001","volume":"92","author":"Z Xia","year":"2019","unstructured":"Xia, Z. et al. Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. Hum. Pathol. 92, 39\u201347 (2019).","journal-title":"Hum. Pathol."},{"key":"28840_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13100-019-0191-2","volume":"11","author":"D Ardeljan","year":"2020","unstructured":"Ardeljan, D. et al. LINE-1 ORF2p expression is nearly imperceptible in human cancers. Mob. DNA 11, 1 (2020).","journal-title":"Mob. DNA"},{"key":"28840_CR33","doi-asserted-by":"crossref","first-page":"M1110.13854","DOI":"10.1074\/mcp.M111.013854","volume":"11","author":"E Kuhn","year":"2012","unstructured":"Kuhn, E. et al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol. Cell. Proteom. 11, M1110.13854 (2012).","journal-title":"Mol. Cell. Proteom."},{"key":"28840_CR34","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1021\/acs.analchem.6b00946","volume":"88","author":"PJ Ippoliti","year":"2016","unstructured":"Ippoliti, P. J. et al. Automated microchromatography enables multiplexing of immunoaffinity enrichment of peptides to greater than 150 for targeted MS-based assays. Anal. Chem. 88, 7548\u20137555 (2016).","journal-title":"Anal. Chem."},{"key":"28840_CR35","doi-asserted-by":"crossref","first-page":"M110.005645","DOI":"10.1074\/mcp.M110.005645","volume":"10","author":"JR Whiteaker","year":"2011","unstructured":"Whiteaker, J. R. et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol. Cell Proteom. 10, M110.005645 (2011).","journal-title":"Mol. Cell Proteom."},{"key":"28840_CR36","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nbt1235","volume":"24","author":"N Rifai","year":"2006","unstructured":"Rifai, N., Gillette, M. A. & Carr, S. A. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat. Biotechnol. 24, 971\u2013983 (2006).","journal-title":"Nat. Biotechnol."},{"key":"28840_CR37","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1373\/clinchem.2009.123935","volume":"55","author":"E Kuhn","year":"2009","unstructured":"Kuhn, E. et al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin. Chem. 55, 1108\u20131117 (2009).","journal-title":"Clin. Chem."},{"key":"28840_CR38","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1074\/mcp.M700354-MCP200","volume":"6","author":"H Keshishian","year":"2007","unstructured":"Keshishian, H., Addona, T., Burgess, M., Kuhn, E. & Carr, S. A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteom. 6, 2212\u20132229 (2007).","journal-title":"Mol. Cell. Proteom."},{"key":"28840_CR39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nmeth.2309","volume":"10","author":"MA Gillette","year":"2013","unstructured":"Gillette, M. A. & Carr, S. A. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat. Methods 10, 28\u201334 (2013).","journal-title":"Nat. Methods"},{"key":"28840_CR40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/pr034086h","volume":"3","author":"NL Anderson","year":"2004","unstructured":"Anderson, N. L. et al. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 3, 235\u2013244 (2004).","journal-title":"J. Proteome Res."},{"key":"28840_CR41","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1073\/pnas.1017300108","volume":"108","author":"AM Karst","year":"2011","unstructured":"Karst, A. M., Levanon, K. & Drapkin, R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl. Acad. Sci. USA 108, 7547\u20137552 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"28840_CR42","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/nprot.2012.097","volume":"7","author":"AM Karst","year":"2012","unstructured":"Karst, A. M. & Drapkin, R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat. Protoc. 7, 1755\u20131764 (2012).","journal-title":"Nat. Protoc."},{"key":"28840_CR43","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1172\/JCI69815","volume":"124","author":"RA Davidowitz","year":"2014","unstructured":"Davidowitz, R. A. et al. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J. Clin. Invest. 124, 2611\u20132625 (2014).","journal-title":"J. Clin. Invest."},{"key":"28840_CR44","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1093\/bioinformatics\/btu148","volume":"30","author":"D Broudy","year":"2014","unstructured":"Broudy, D. et al. A framework for installable external tools in Skyline. Bioinformatics 30, 2521\u20132523 (2014).","journal-title":"Bioinformatics"},{"key":"28840_CR45","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/1078-0432.CCR-16-1237","volume":"23","author":"JF Liu","year":"2017","unstructured":"Liu, J. F. et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin. Cancer Res. 23, 1263\u20131273 (2017).","journal-title":"Clin. Cancer Res."},{"key":"28840_CR46","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/bioinformatics\/btu305","volume":"30","author":"M Choi","year":"2014","unstructured":"Choi, M. et al. MSstats: An R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics 30, 2524\u20132526 (2014).","journal-title":"Bioinformatics"},{"key":"28840_CR47","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2015.1618","volume":"1","author":"AS McDaniel","year":"2015","unstructured":"McDaniel, A. S. et al. Next-generation sequencing of tubal intraepithelial carcinomas. JAMA Oncol. 1, 1128\u20131132 (2015).","journal-title":"JAMA Oncol."},{"key":"28840_CR48","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","volume":"6","author":"MA Eckert","year":"2016","unstructured":"Eckert, M. A. et al. Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube. Cancer Discov. 6, 1342\u20131351 (2016).","journal-title":"Cancer Discov."},{"key":"28840_CR49","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy, S. I. et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 8, 1093 (2017).","journal-title":"Nat. Commun."},{"key":"28840_CR50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5219","volume":"248","author":"R-C Wu","year":"2019","unstructured":"Wu, R.-C. et al. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. J. Pathol. 248, 41\u201350 (2019).","journal-title":"J. Pathol."},{"key":"28840_CR51","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1016\/j.celrep.2018.05.090","volume":"23","author":"THM Nguyen","year":"2018","unstructured":"Nguyen, T. H. M. et al. L1 retrotransposon heterogeneity in ovarian tumor cell evolution. Cell Rep. 23, 3730\u20133740 (2018).","journal-title":"Cell Rep."},{"key":"28840_CR52","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/cancers12030764","volume":"12","author":"W Zhang","year":"2020","unstructured":"Zhang, W. et al. Global DNA hypomethylation in epithelial ovarian cancer: Passive demethylation and association with genomic instability. Cancers 12, 764 (2020).","journal-title":"Cancers"},{"key":"28840_CR53","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1358\/dof.2013.38.8.1980499","volume":"38","author":"EA Griffiths","year":"2013","unstructured":"Griffiths, E. A. et al. SGI-110: DNA Methyltransferase Inhibitor Oncolytic. Drugs Future 38, 535\u2013543 (2013).","journal-title":"Drugs Future"},{"key":"28840_CR54","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1158\/0008-5472.CAN-07-0251","volume":"67","author":"CB Yoo","year":"2007","unstructured":"Yoo, C. B. et al. Delivery of 5-aza-2\u2019-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 67, 6400\u20136408 (2007).","journal-title":"Cancer Res."},{"key":"28840_CR55","first-page":"E733","volume":"114","author":"Z Tang","year":"2017","unstructured":"Tang, Z. et al. Human transposon insertion profiling: Analysis, visualization and identification of somatic LINE-1 insertions in ovarian cancer. Proc. Natl. Acad. Sci. USA 114, E733\u2013E740 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"28840_CR56","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/nm.3919","volume":"21","author":"N Rodi\u0107","year":"2015","unstructured":"Rodi\u0107, N. et al. Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. Nat. Med. 21, 1060\u20131064 (2015).","journal-title":"Nat. Med."},{"key":"28840_CR57","first-page":"4894","volume":"112","author":"TT Doucet-O\u2019Hare","year":"2015","unstructured":"Doucet-O\u2019Hare, T. T. et al. LINE-1 expression and retrotransposition in Barrett\u2019s esophagus and esophageal carcinoma. Proc. Natl. Acad. Sci. USA 112, 4894\u20134900 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"28840_CR58","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/cncr.10917","volume":"95","author":"P Sedlaczek","year":"2002","unstructured":"Sedlaczek, P. et al. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer 95, 1886\u20131893 (2002).","journal-title":"Cancer"},{"key":"28840_CR59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1196\/annals.1448.011","volume":"1137","author":"E Sunami","year":"2008","unstructured":"Sunami, E., Vu, A.-T., Nguyen, S. L., Giuliano, A. E. & Hoon, D. S. B. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann. N. Y. Acad. Sci. 1137, 171\u2013174 (2008).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"28840_CR60","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/jid.2012.36","volume":"132","author":"S Hoshimoto","year":"2012","unstructured":"Hoshimoto, S. et al. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J. Invest. Dermatol. 132, 1689\u20131697 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"28840_CR61","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.18632\/oncotarget.14439","volume":"8","author":"Y Nagai","year":"2017","unstructured":"Nagai, Y. et al. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. Oncotarget 8, 11906\u201311916 (2017).","journal-title":"Oncotarget"},{"key":"28840_CR62","doi-asserted-by":"crossref","first-page":"9491","DOI":"10.1021\/acsnano.0c02378","volume":"14","author":"L Cohen","year":"2020","unstructured":"Cohen, L. et al. Single molecule protein detection with attomolar sensitivity using droplet digital enzyme-linked immunosorbent assay. ACS Nano 14, 9491\u20139501 (2020).","journal-title":"ACS Nano"},{"key":"28840_CR63","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.18632\/oncotarget.1821","volume":"5","author":"K Maes","year":"2014","unstructured":"Maes, K. et al. The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget 5, 3115\u20133129 (2014).","journal-title":"Oncotarget"},{"key":"28840_CR64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann, C. & Lyko, F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123, 8\u201313 (2008).","journal-title":"Int. J. Cancer"},{"key":"28840_CR65","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1101\/gad.343186.120","volume":"34","author":"B Tiwari","year":"2020","unstructured":"Tiwari, B. et al. p53 directly represses human LINE1 transposons. Genes Dev. 34, 1439\u20131451 (2020).","journal-title":"Genes Dev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28840-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T18:40:50Z","timestamp":1701801650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28840-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["28840"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-28840-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R. Drapkin serves on the scientific advisory board of Repare Therapeutics and VOC Health. None of the other authors declare any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1537"}}